Liberum Capital reissued their buy rating on shares of PureCircle (LON:PURE) in a report released on Monday morning. Liberum Capital currently has a GBX 500 ($6.73) target price on the stock.

Separately, Kepler Capital Markets reiterated a reduce rating and set a GBX 390 ($5.25) price objective on shares of PureCircle in a report on Friday, November 17th.

Shares of PureCircle (LON:PURE) traded down GBX 13 ($0.17) during midday trading on Monday, hitting GBX 475 ($6.39). 43,074 shares of the stock were exchanged, compared to its average volume of 74,680. PureCircle has a 52-week low of GBX 192 ($2.58) and a 52-week high of GBX 517 ($6.96).

In related news, insider Christopher Dale Pratt sold 44,630 shares of the business’s stock in a transaction dated Thursday, September 21st. The shares were sold at an average price of GBX 460 ($6.19), for a total transaction of £205,298 ($276,309.56).

WARNING: “PureCircle (PURE) Given Buy Rating at Liberum Capital” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/12/05/purecircle-pure-given-buy-rating-at-liberum-capital.html.

PureCircle Company Profile

PureCircle Limited is a producer of stevia ingredients for the global food and beverage industry. The Company focuses on encouraging healthier diets around the world through the supply of natural ingredients to the global food and beverage industry. The Company has over 40 stevia-related patents. The Company’s Zeta Family ingredients consists of the sugar, such as steviol glycosides, including Reb M and Reb D, and allow for the deepest calorie reductions by food and beverage companies.

Receive News & Stock Ratings for PureCircle Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureCircle Limited and related stocks with our FREE daily email newsletter.